Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis.

Özcan, Alaz; Sahin, Dilara; Impellizzieri, Daniela; Nguyen, Tuan T; Hafner, Jürg; Yawalkar, Nikhil; Kurzbach, Dennis; Tan, Ge; Akdis, Cezmi A; Nilsson, Jakob; Boyman, Onur; Kolios, Antonios G A (2020). Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis. Journal of investigative dermatology, 140(5), 1003-1014.e8. Elsevier 10.1016/j.jid.2019.09.018

[img]
Preview
Text
yawalkar 2.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (47MB) | Preview

Methotrexate (MTX) is an anti-proliferative drug used for treating inflammatory diseases including psoriasis. Nevertheless, its use in localized therapy is impeded due to poor transdermal penetration. We show that MTX coupled with gold-nanoparticles (GNPs) demonstrates superior anti-inflammatory efficacy compared to MTX-alone in an imiquimod (IMQ)-induced mouse model, significantly reducing γδ T cells, CD4+ T cells, and neutrophils. Furthermore, it was well tolerated upon systemic and topical administration. In an AGR129 human xenograft mouse model, two-week topical treatment with MTX-GNPs inhibited skin hyperplasia significantly better than topical calcipotriol-betamethasone (TCB) and led to profound tissue remodeling, involving upregulation of extracellular matrix reorganization and downregulation of cornification and keratinization processes. The number of resident T cells in the grafts as well as IL-17 production drastically decreased upon MTX-GNP treatment. While both MTX and MTX-GNPs directly prevented proliferation and induced apoptosis of T cells, suppression of cytokine production was a shared mechanism of GNP and MTX-GNPs. In conclusion, MTX-GNPs influence immune and stromal components of the skin, leading to potent inhibition of pathogenesis in preclinical psoriasis. MTX-GNPs surpass the efficacy of conventional MTX and standard of care, emerging as a non-steroidal, topical alternative for psoriasis treatment.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Yawalkar, Nikhil

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0022-202X

Publisher:

Elsevier

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

30 Dec 2019 08:37

Last Modified:

01 Nov 2020 02:30

Publisher DOI:

10.1016/j.jid.2019.09.018

PubMed ID:

31678057

BORIS DOI:

10.7892/boris.136783

URI:

https://boris.unibe.ch/id/eprint/136783

Actions (login required)

Edit item Edit item
Provide Feedback